MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
February 27, 2024 10:30 ET | MAIA Biotechnology, Inc.
New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA...
AMR Logo.png
Global Chronic Hepatitis B (CHB) Market to Reach USD 6.1 Billion by 2031: Says AMR
November 01, 2022 03:38 ET | Allied Market Research
Portland, OR, Nov. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Chronic Hepatitis B (CHB) Market size was estimated at $4.6 billion in 2021...
BioNTech schließt Üb
BioNTech schließt Übernahme von Kites Neoantigen-TCR Zelltherapie-Plattform und Produktionsanlagen im amerikanischen Gaithersburg ab
August 04, 2021 07:00 ET | BioNTech SE
MAINZ, Deutschland & Santa Monica, USA, 4. August 2021 – BioNTech SE (Nasdaq: BNTX, „BioNTech”) und Kite, ein Unternehmen der Gilead-Gruppe (Nasdaq: GILD, „Kite”) gaben heute bekannt, dass...
BioNTech Completes A
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
August 04, 2021 07:00 ET | BioNTech SE
MAINZ, Germany & Santa Monica, USA, August 4, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the...
Global Oral Solid Dosage Excipients Market estimated to be US$ 5.9 billion by 2030 with a CAGR of 7.9% during the forecast period - by PMI
March 02, 2021 10:05 ET | PMI
Covina CA, March 02, 2021 (GLOBE NEWSWIRE) -- Global Oral Solid Dosage Excipients Market accounted for US$ 2.8 billion in 2020 and is estimated to be US$ 5.9 billion by 2030 and is anticipated to...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout
September 14, 2020 13:59 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches...
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
September 01, 2020 08:30 ET | Jounce Therapeutics, Inc.
  – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...
Global Rheumatoid Arthritis Therapeutics Market; High adoption of disease-modifying antirheumatic drugs (DMARDs) will boost the market - PMI
June 25, 2020 10:35 ET | PMI
Covina, CA, June 25, 2020 (GLOBE NEWSWIRE) -- The global rheumatoid arthritis therapeutics market accounted for US$ 25.7 billion in 2019 and is estimated to be US$ 39.8 billion by 2029 and is...
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
April 17, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...